AVLN

28.6250.26%
KH

Kathryn Haviland

Independent Chair of the Board

Ms. Kathryn Haviland, also known as Kate, M.B.A, has been an Independent Director at Avalyn Pharma Inc. since March 2026. She is Chair of Board at GC Therapeutics, Inc. since December 2025. She served as President and Chief Executive Officer of Blueprint Medicines Corporation, or Blueprint, a clinical-stage biopharmaceutical company, from April 2022 to SANOFI’s acquisition of Blueprint in July 2025. Prior to serving as President and Chief Executive Officer, Ms. Haviland served as Chief Operating Officer of Blueprint from January 2019 to April 2022 and as Chief Business Officer from January 2016 to January 2019. Prior to joining Blueprint, Ms. Haviland served as vice president, rare diseases and oncology program leadership at Idera Pharmaceuticals, Inc. (acquired by Aceragen, Inc.), a biopharmaceutical company, from April 2014 to December 2015, as head of commercial development at Sarepta Therapeutics, Inc., a public biopharmaceutical and drug development company, from June 2012 to April 2014, as executive director of commercial development at PTC Therapeutics, Inc. (Nasdaq: PTCT), a public biopharmaceutical company, from March 2007 to June 2012 and roles in corporate development and project management at Genzyme, Inc. (acquired by SANOFI, a global healthcare company) from July 2005 to March 2007. Ms. Haviland has served on the board of directors of Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a public biopharmaceutical company, since June 2018 and as chair of the board of directors since January 2022. Ms. Haviland has also served on the board of directors of Bicara Therapeutics Inc. since September 2023. Ms. Haviland received her M.B.A. from Harvard Business School and her B.A. in Biochemistry/Molecular Biology and Economics from Wesleyan University.

Positions